5-(3-Methyl-[1,2,4]oxadiazol-5-yl)-1,4,5,6-tetrahydro-pyrimidine; TFA

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(3-Methyl-[1,2,4]oxadiazol-5-yl)-1,4,5,6-tetrahydro-pyrimidine; TFA
• 英文别名: 3-methyl-5-(1,4,5,6-tetrahydropyrimidin-5-yl)-1,2,4-oxadiazole
• 化学式: C₇H₁₀N₄O
• 分子量: 166.18
• InChiKey: SBTJKJXNBNKFHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(triphenylmethyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine 以0%的产率得到
  参考文献：
  名称：

  Dunbar Philip G., Durant Graham J., Fang Zheng, Abuh Yahaya F., El-Assadi+, J. Med. Chem., 36 (1993) N 7, S 842-847

  摘要：

  DOI：

文献信息

• Dunbar Philip G., Durant Graham J., Fang Zheng, Abuh Yahaya F., El-Assadi+, J. Med. Chem., 36 (1993) N 7, S 842-847
  作者：Dunbar Philip G., Durant Graham J., Fang Zheng, Abuh Yahaya F., El-Assadi+

  DOI：——

  日期：——
• MUSCARINIC AGONISTS
  申请人：THE UNIVERSITY OF TOLEDO

  公开号：EP0630244A1

  公开（公告）日：1994-12-28
• EP0630244A4
  申请人：——

  公开号：EP0630244A4

  公开（公告）日：1994-04-07
• Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating
  申请人：NeuroSolis, Inc.

  公开号：US20170313687A1

  公开（公告）日：2017-11-02

  Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.
• Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating
  申请人：NeuroSolis, Inc.

  公开号：US20180099956A1

  公开（公告）日：2018-04-12

  The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.